LancetRCT
Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up)
results of two phase 3 randomised controlled studies.
ConclusionUpadacitinib 15 mg daily provides clinically meaningful repigmentation of both the face and total body for adults and adolescents with non-segmental vitiligo, with no new safety signals identified.
Passeron T, Prajapati VH, … senior author Seneschal JThe Lancet